Memantine Hydrochloride Solution
Product Images NDC 68999-943

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 68999-943). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Governmental & Specialty Rx, Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

"image Description" (Memantine Hydro Cup Label)

This is a description for a medication - Memantine hydrochloride oral solution in a 5 mL delivery format. It has a National Drug Code (NDC) of 68999-343-05 and is designed for institutional use only. The medication is manufactured by Chartwell Governmental & Specialty RX, LLC located in Congers, NY 10920. Please refer to the insert or leaflet for additional information.*

FDA Label Image

"image Description" (Memantine Hydro Fig 1)

This text shows the Mean Change from Baseline in ADCS-ADL Score for treatment with Placebo and Memantine over 4, 12, and 28 weeks. The data indicates clinical improvement or decline based on the values provided.*

FDA Label Image

"image Description" (Memantine Hydro Fig 2)

FDA Label Image

"image Description" (Memantine Hydro Fig 3)

This text provides a chart showing the clinical improvement and decline over weeks of treatment with placebo and memantine. The data appears to compare the effects of these two treatments on patient outcomes.*

FDA Label Image

"image Description" (Memantine Hydro Fig 4)

This is a chart showing the Cumulative Percentage of SIB (Stereotypic Inappropriate Behaviors) change from baseline for a certain treatment (possibly memantine) over a period of time. The chart ranges from -15 to 25, with placeholders indicating the progression of change at 5 to 10 intervals.*

FDA Label Image

"image Description" (Memantine Hydro Fig 5)

FDA Label Image

"image Description" (Memantine Hydro Fig 6)

This is a graph showing the cumulative percentage of patients on Placebo/Donepezil and Memantine/Donepezil based on the change in ADCS-ADL score from baseline. The x-axis represents the ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients.*

FDA Label Image

"image Description" (Memantine Hydro Fig 7)

Mean Change from Baseline in SIB Score over weeks of treatment is compared between Placebo/Donepezil and Memantine/Donepezil groups. The graph shows clinical improvement in the Memantine/Donepezil group and clinical decline in the Placebo/Donepezil group.*

FDA Label Image

"image Description" (Memantine Hydro Fig 8)

FDA Label Image

"image Description" (Memantine Hydro Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.